First Author: L.Karabas TURKEY
Co Author(s): B. Ozkan H. Kose S. Kaya
Back to previous
To evaluate the effect of intravitreal dexamethazone injection to the fellow untreated eye’s visual acuity and central macular thickness in patients with diabetic macular edema.
Kocaeli University School of Medicine, Ophthalmology Dept, Kocaeli, TURKEY
Records of 20 treatment naive diabetic macular edema patients who underwent intravitreal dexamethasone injection were evaluated retrospectively. The outcome factors evaluated were visual acuity and central macular thickness of the fellow untreated eye.
There was no significant difference between the pre-injection visual acuity and post-injection 1st month, 2nd month and 3rd month visual acuity of the fellow eye (p>0,05). The mean pre-injection central macular thickness was 388,94 ±27,15μ. The post-injection 1st month, 2nd month and 3rd month central macular thicknesses were 346,94±22,40, 335,84 ±21,06 and 320,42±17,91 , respectively. There was statistically significant difference between pre-injection central macular thickness and post-injection 1st month, 2nd month and 3rd month central macular thicknesses (p=0,01, p=0,001 and p=0,004)
The results of the study show that injection of the dexamethasone implant decreases the diabetic macular edema in the fellow untreated eye. We believe that the drug that passes to the systemic circulation might be the reason for the decrease in the fellow untreated eye.